A prospective, non-interventional, observational study of presentation, treatment patterns and outcomes in Atypical Hemolytic Uremic Syndrome patients

Trial Identifier: D7413R00001
Sponsor: AstraZeneca
Start Date: January 2024
Primary Completion Date: December 2027
Study Completion Date: December 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Baoding, China
China Beijing, China
China Changsha, China
China Chengdu, China
China Chongqing, China
China Foshan, China
China Fuzhou, China
China Guangzhou, China
China Guizhou, China
China Haikou, China
China Hangzhou, China
China Hefei, China
China Huai'an, China
China Jinan, China
China Luoyang, China
China Nanchang, China
China Nanchong, China
China Nanjing, China
China Nanning, China
China Ningbo, China
China Qingdao, China
China Shanghai, China
China Shenyang, China
China Shenzhen, China
China Shijiazhuang, China
China Suzhou, China
China Taiyuan, China
China Tianjin, China
China Wuhan, China
China Wulumuqi, China
China Xiamen, China
China Xian, China
China Xuzhou, China
China Zhengzhou, China
China, Beijing Beijing, China
China, Sichuan Luzhou, Sichuan, China